Manufacturer
KOTRA PHARMA (M) SDN. BHD.
Contents
Fluconazole
Indication
Cryptococcosis ie, cryptococcal meningitis & infections of other sites (eg, pulmonary, cutaneous). Maintenance therapy to prevent relapse of cryptococcal disease in patients w/ AIDS. Systemic candidiasis ie, candidemia, disseminated candidiasis & other forms of invasive candidal infection. Mucosal candidiasis. Prevention of oropharyngeal candidiasis relapse in patients w/ AIDS. Acute or recurrent genital & vag candidiasis; prophylaxis to reduce incidence of recurrent vag candidiasis. Candidal balanitis. Prevention of fungal infections in patient w/ malignancy who are predisposed to such infections as a result of cytotoxic chemo- or radiotherapy. Dermatomycosis ie, tinea pedis, corporis, cruris & versicolor; dermal candida infections.
Instruction
May be taken with or without food.
Drug interaction
Increased prothrombin time w/ warfarin. Increased conc & psychomotor effects of midazolam. Increased risk of ventricular arrythmia w/ cisapride, pimozide. Increased conc of cyclosporin. Increased plasma conc by hydrochlorothiazide. Increased levels of phenytoin, zidovudine. Increased serum levels of rifabutin, tacrolimus, astemizole & other CYP450-metabolised drugs. Decreased AUC & shorter t½ w/ rifampicin. Prolonged serum t½ of sulfonylureas eg, chlorpropamide, glibenclamide, glipizide & tolbutamide. Prolonged QTc interval w/ terfenadine. Decreased mean plasma clearance rate of theophylline.
Malaysia
